Ultragenyx Pharmaceutical (RARE)

The company’s commercial portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is used to treat X-linked hypophosphatemia, a rare inherited disorder that affects phosphate regulation and bone development, and has become a key product for Ultragenyx. Mepsevii treats mucopolysaccharidosis VII, an inherited lysosomal storage disease, while Dojolvi is indicated for certain long-chain fatty acid oxidation disorders. These products reflect Ultragenyx’s strategy of addressing small patient populations where effective therapies can command specialist pricing and require close engagement with physicians, payers, and patient communities.

Ultragenyx also maintains a development pipeline across several therapeutic areas linked to rare genetic conditions, including metabolic, bone, endocrine, and neurological disorders. Its approach often involves partnerships, licensing arrangements, and technology platforms that can support multiple programmes, including gene therapy and biologics.

The company operates internationally across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, although North America is its largest revenue contributor. As a listed rare disease specialist, Ultragenyx is shaped by clinical trial outcomes, regulatory decisions, reimbursement negotiations, and the durability of demand for its approved therapies.